JPWO2020092467A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020092467A5 JPWO2020092467A5 JP2021523839A JP2021523839A JPWO2020092467A5 JP WO2020092467 A5 JPWO2020092467 A5 JP WO2020092467A5 JP 2021523839 A JP2021523839 A JP 2021523839A JP 2021523839 A JP2021523839 A JP 2021523839A JP WO2020092467 A5 JPWO2020092467 A5 JP WO2020092467A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- car
- cdr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752889P | 2018-10-30 | 2018-10-30 | |
| US62/752,889 | 2018-10-30 | ||
| PCT/US2019/058710 WO2020092467A1 (en) | 2018-10-30 | 2019-10-30 | Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022512891A JP2022512891A (ja) | 2022-02-07 |
| JP2022512891A5 JP2022512891A5 (https=) | 2022-10-28 |
| JPWO2020092467A5 true JPWO2020092467A5 (https=) | 2022-10-28 |
| JP7548584B2 JP7548584B2 (ja) | 2024-09-10 |
Family
ID=70464551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523839A Active JP7548584B2 (ja) | 2018-10-30 | 2019-10-30 | 抗ｃｄ７９ｂ抗体およびキメラ抗原レセプターおよびそれらの使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12454574B2 (https=) |
| EP (1) | EP3873939A4 (https=) |
| JP (1) | JP7548584B2 (https=) |
| KR (1) | KR20210098454A (https=) |
| CN (1) | CN113227145A (https=) |
| AU (1) | AU2019370276A1 (https=) |
| CA (1) | CA3118337A1 (https=) |
| WO (1) | WO2020092467A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019370276A1 (en) | 2018-10-30 | 2021-06-10 | Board Of Regents, The University Of Texas System | Anti-CD79b antibodies and chimeric antigen receptors and methods of use thereof |
| US20230183371A1 (en) * | 2020-04-30 | 2023-06-15 | Board Of Regents, The University Of Texas System | Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| MX2023014352A (es) * | 2021-06-01 | 2024-03-14 | Janssen Biotech Inc | Anticuerpos antiidiotipicos contra anticuerpos anti-cd79b. |
| CN114891123B (zh) * | 2022-06-09 | 2024-02-09 | 北京美康基免生物科技有限公司 | 一种基于CD79b人源化抗体的嵌合抗原受体及其应用 |
| IL317811A (en) | 2022-07-25 | 2025-02-01 | Interius Biotherapeutics Inc | Mutated polypeptides, compositions containing them and uses thereof |
| TWI894742B (zh) * | 2022-12-29 | 2025-08-21 | 美商Ｌｔｚ治療股份有限公司 | 抗CD79b抗體及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ292061B6 (cs) | 1994-03-17 | 2003-07-16 | Merck Patent Gmbh | Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
| CA2882022A1 (en) | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| NZ583318A (en) | 2007-07-16 | 2012-07-27 | Genentech Inc | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| CN105102480B (zh) | 2012-12-24 | 2019-04-16 | 艾伯维公司 | 催乳素受体结合蛋白及其用途 |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| MA40938A (fr) | 2014-12-05 | 2017-10-11 | Hoffmann La Roche | Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps |
| CN107613974B (zh) | 2015-03-16 | 2021-01-15 | 塞尔德克斯医疗公司 | 抗-met抗体及其使用方法 |
| CA2984624A1 (en) | 2015-03-18 | 2016-09-22 | Baylor College Of Medicine | Her2/erbb2 chimeric antigen receptor |
| CN107708741A (zh) * | 2015-06-12 | 2018-02-16 | 免疫医疗公司 | 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法 |
| AU2016297014B2 (en) * | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| WO2017120280A1 (en) | 2016-01-06 | 2017-07-13 | Virginia Tech Intellectual Properties, Inc. | Antigen targeting to porcine langerin |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| SI3468586T1 (sl) | 2016-06-14 | 2025-01-31 | Xencor, Inc. | Bispecifična protitelesa za zaviralce kontrolnih točk |
| CN108276493B (zh) | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| CA3063169A1 (en) | 2017-06-07 | 2018-12-13 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
| CA3070295A1 (en) | 2017-07-28 | 2019-01-31 | Phanes Therapeutics, Inc. | Anti-tim-3 antibodies and uses thereof |
| CN111655286A (zh) | 2017-08-11 | 2020-09-11 | 布林克生物医学简易股份公司 | 作为免疫调节剂的cd96结合剂 |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| CN109265565B (zh) * | 2018-10-10 | 2021-06-01 | 苏州大学 | 一种携带分子开关的抗CD79b嵌合抗原受体及其修饰的免疫细胞和应用 |
| AU2019370276A1 (en) | 2018-10-30 | 2021-06-10 | Board Of Regents, The University Of Texas System | Anti-CD79b antibodies and chimeric antigen receptors and methods of use thereof |
-
2019
- 2019-10-30 AU AU2019370276A patent/AU2019370276A1/en active Pending
- 2019-10-30 EP EP19878006.6A patent/EP3873939A4/en active Pending
- 2019-10-30 CA CA3118337A patent/CA3118337A1/en active Pending
- 2019-10-30 WO PCT/US2019/058710 patent/WO2020092467A1/en not_active Ceased
- 2019-10-30 KR KR1020217016410A patent/KR20210098454A/ko not_active Withdrawn
- 2019-10-30 JP JP2021523839A patent/JP7548584B2/ja active Active
- 2019-10-30 US US17/309,144 patent/US12454574B2/en active Active
- 2019-10-30 CN CN201980085366.4A patent/CN113227145A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krishnamurthy et al. | Bispecific antibodies for cancer therapy: A review | |
| RU2018139339A (ru) | Новые биспецифические полипептиды против cd137 | |
| Nuñez-Prado et al. | The coming of age of engineered multivalent antibodies | |
| JP2019523630A5 (https=) | ||
| CN115232209B (zh) | 靶向gprc5d的抗体及其用途 | |
| CN110551221A (zh) | 一种双特异性抗体及其制备方法与应用 | |
| JPWO2020014285A5 (https=) | ||
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| CN113150156B (zh) | 抗tigit抗体及其用途 | |
| CN117836328A (zh) | 一种多特异性抗原结合蛋白及其应用 | |
| WO2023051414A1 (zh) | 靶向间皮素的抗体及其用途 | |
| JPWO2020092467A5 (https=) | ||
| WO2024113099A1 (en) | Protease cleavable recombinant bispecific antibodies and compositions and uses thereof | |
| WO2021113748A1 (en) | Composition of triaxial antibodies and method of making and using thereof | |
| US20260055201A1 (en) | Bispecific antibody and use thereof | |
| US20240101701A1 (en) | Antibody-derived t cell activating technologies | |
| CN115246885B (zh) | 一种双特异性抗体及其应用 | |
| CN116063527A (zh) | 靶向间皮素的抗体及其用途 | |
| AU2018262648B2 (en) | Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis | |
| JPWO2023079102A5 (https=) | ||
| EP4603509A1 (en) | Multifunctional recombinant antibody, and preparation method and use therefor | |
| JPWO2023062604A5 (https=) | ||
| EP4682172A1 (en) | Anti-muc17, anti-cd3 and anti-cd28 trispecific antibody | |
| KR20260032990A (ko) | Her2 키메라 항원 수용체 분비 | |
| CN121666446A (zh) | Gpc3嵌合抗原受体分泌 |